Clinical trialPhase 1Terminated
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
- Outcome
- Stopped earlyTerminated due to slow accrual (Enrollment)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- May 2010
- Expected end
- June 2013
- Enrollment
- 3 participants
- Sites
- 2
- Primary outcomes
- To evaluate the safety of using the combination of gemcitabine and bosutinib in the postoperative adjuvant treatment of patients with completely resected pancreatic cancer.; To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination
- Sponsor
- Other
- Results posted
- No
- Last update
- 9 May 2014
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.